title: Brief Report: Prolonged Viral Suppression Over a 12-Year Follow-up of HIV-Infected Patients: The Persistent Impact of Adherence at 4 Months After Initiation of Combined Antiretroviral Therapy in the ANRS CO8 APROCO-COPILOTE Cohort.
abstract: The effect of early adherence on long-term viral suppression was assessed among 1281 patients with HIV starting a protease inhibitor-containing regimen in 1997-1999, followed up to 12 years. Association between 4-month adherence (3-level score) and prolonged viral suppression was evaluated using a multivariate mixed logistic model in 891 eligible patients. High 4-months adherence [odds ratio (95% confidence interval): 3.72 (1.98 to 6.98)] was associated with long-term prolonged viral suppression, irrespective of maintenance adherence. This unexpected long-term virological impact of early adherence reinforces the message that, when starting antiretrovirals, all means should be mobilized to ensure optimum early adherence to achieve prolonged antiretroviral success.
authors.affiliation: *INSERM, UMR_S 912 (SESSTIM), Marseille, France; †Aix Marseille Université, UMR_S 912, IRD, Marseille, France; ‡ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France; §CMIT, Paris, France; ‖Hôpital St Antoine, Paris, France; ¶INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health, Bordeaux, France; #CHU Dijon, Dijon, France; **Université Paris Diderot, INSERM, IAME, UMR 1137, Paris, France; ††CERMES (CNRS-INSERM-EHESS), Paris, France; and ‡‡Unité de Coordination du Risque Épidémique et Biologique, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Camelia
authors.initials: C
authors.lastname: Protopopescu
authors.forename: Maria P
authors.initials: MP
authors.lastname: Carrieri
authors.forename: François
authors.initials: F
authors.lastname: Raffi
authors.forename: Odile
authors.initials: O
authors.lastname: Picard
authors.forename: Lucile
authors.initials: L
authors.lastname: Hardel
authors.forename: Lionel
authors.initials: L
authors.lastname: Piroth
authors.forename: Corinne
authors.initials: C
authors.lastname: Jadand
authors.forename: Janine
authors.initials: J
authors.lastname: Pierret
authors.forename: Bruno
authors.initials: B
authors.lastname: Spire
authors.forename: Catherine
authors.initials: C
authors.lastname: Leport
mesh_terms: D000328:Adult; D000873:Anthracenes; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology / Q000821:virology*; D006801:Humans; D008297:Male; D055118:Medication Adherence; D011446:Prospective Studies; D000072230:Sustained Virologic Response; D013997:Time Factors
chemical_list: D000873:Anthracenes; D044966:Anti-Retroviral Agents; C040207:compound A 12